Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,692Revenue $M2,820Net Margin (%)12.3Z-Score24.2
Enterprise Value $M48,249EPS $3.1Operating Margin %29.7F-Score5
P/E(ttm))155Cash Flow Per Share $-2.0Pre-tax Margin (%)27.5Higher ROA y-yN
Price/Book19.010-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsY
Price/Sales19.25-y EBITDA Growth Rate %0Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %2.8ROA % (ttm)10.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)15.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M103ROI % (ttm)53.3Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 474.5017%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 474.5017%Sold Out0
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 474.5029%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 474.5029%New holding583
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 474.5037%Add 60.34%2,795,500
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 474.5037%New holding881
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 474.5037%New holding2,295
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 474.5035%Add 23.47%1,743,468
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 474.5035%New holding6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 474.5039%Sold Out0
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 474.5045%New holding3,285
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 474.5064%Add 170.41%1,412,100
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 474.5072%Reduce -24.56%522,200
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 474.5081%Sold Out0
REGNCarl Icahn 2011-09-30 Sold Out -1.76%$44.96 - $72.19
($58.66)
$ 474.5088%Sold Out0
REGNDodge & Cox 2011-09-30 Reduce-0.03%$44.96 - $72.19
($58.66)
$ 474.5088%Reduce -97.62%9,400
REGNVanguard Health Care Fund 2011-09-30 Add0.03%$44.96 - $72.19
($58.22)
$ 474.5088%Add 15.37%692,200
REGNDodge & Cox 2011-03-31 Buy 0.02%$32.61 - $44.68
($36.41)
$ 474.5092%New holding375,685
REGNVanguard Health Care Fund 2011-03-31 Reduce$32.61 - $44.94
($36.59)
$ 474.5092%Reduce -3.21%600,000
REGNSeth Klarman 2011-03-31 Sold Out $32.61 - $44.68
($36.41)
$ 474.5092%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAKER CHARLES ADirector 2015-03-25Sell5,000$454.965.52view
Aberman Michael SSVP Strategy Investor Relation 2015-03-24Sell4,843$478.990.23view
Aberman Michael SSVP Strategy Investor Relation 2015-03-18Sell3,442$4653.24view
Terifay Robert JSVP Commercial 2015-03-17Sell10,993$451.016.45view
LAROSA JOSEPH JSVP General Counsel and Secret 2015-03-16Sell18,311$4506.68view
McCorkle Douglas SVP Controller and Asst Treasur 2015-02-27Sell3,000$416.2415.34view
Tessier-Lavigne MarcDirector 2015-02-26Sell3,000$421.9513.78view
Terifay Robert JSVP Commercial 2015-02-24Sell11,173$423.6713.31view
Aberman Michael SSVP Strategy Investor Relation 2015-02-24Sell3,374$418.4814.72view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-02-23Sell9,431$427.8212.22view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 

    More From Our Partners
    Stock Market News for April 09, 2015 - Market News Apr 9 2015 - ZACKS

    More From Other Websites
    U.S. benchmarks chip away at major resistance Apr 23 2015
    Amgen: But What About the Biosimilars? Apr 22 2015
    Regeneron Bounces Higher Off Support Apr 22 2015
    Amgen tops estimates with 51 percent spike in 1Q profit Apr 21 2015
    Amgen tops estimates with 51 percent spike in 1Q profit Apr 21 2015
    BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable Apr 20 2015
    Cuomo's headed for Cuba, but don't expect a 'Nixon goes to China' moment Apr 20 2015
    Cuba Mission by Cuomo May Boost Democrats in Swing-State Florida Apr 19 2015
    How Marketing And Media Muddled The Truth About The Heart Drug Vytorin Apr 16 2015
    Regeneron CEO Joins Cuba Trade Trip With New York Governor Cuomo Apr 15 2015
    Another bad year for stockpickers? Goldman Sachs thinks so Apr 14 2015
    Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
    Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
    Cramer: How to play the Apple downgrade Apr 08 2015
    Stock Market News for April 08, 2015 - Market News Apr 08 2015
    Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM)... Apr 07 2015
    FedEx gains on TNT deal; GM slides as Canada unwinds stake Apr 07 2015
    Don't Miss Your Chance To Buy This High-Ranking Biotech On Sale Apr 03 2015
    Biotech run near an end? Apr 02 2015
    Economic Indicators Move Equities and Bonds Apr 01 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK